{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:58:37Z","timestamp":1788274717614,"version":"build-2803163510"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Janus kinase (JAK) family members, as upstream regulators, phosphorylate not only themselves but also cytokine receptors and signal transducer and activator of transcription (STAT) proteins in the JAK-STAT signaling pathway. The JAK-STAT pathway is associated with various cellular processes, such as cell proliferation, cell death, and immune responses. Considering that the JAK-STAT pathway is involved in immunity, dysfunctional JAKs can cause autoimmune diseases, including rheumatoid arthritis. Therefore, several inhibitors have been developed to inhibit the function of JAKs in the case of abnormal JAK-STAT signaling. Emerging structural data on JAKs highlight the opportunities to design selective inhibitors that can overcome mutation-driven resistance. Therefore, novel JAK inhibitors need to be developed. In this review, we discuss the principal structural features of JAKs, focusing on the active site. In addition, we summarized the updated JAK inhibitors indicated for rheumatoid arthritis that are available in the pharmaceutical market. The binding modes of JAK inhibitors have also been described. Based on the structural analysis of JAKs and their inhibitors, we propose strategies for developing next-generation JAK inhibitors.<\/jats:p>","DOI":"10.3389\/fmed.2026.1716179","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:10:01Z","timestamp":1769411401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Revisiting Janus kinases as molecular drug targets for rheumatic diseases"],"prefix":"10.3389","volume":"13","author":[{"given":"Sunghark","family":"Kwon","sequence":"first","affiliation":[{"name":"Bright College, Hankyong National University","place":["Anseong, Republic of Korea"]},{"name":"Gyeonggi Regional Research Center, Hankyong National University","place":["Anseong, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.bbamcr.2007.01.002","article-title":"Regulation of MAPKs by growth factors and receptor tyrosine kinases","volume":"1773","author":"Katz","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.cell.2007.10.033","article-title":"SnapShot: JAK-STAT signaling","volume":"131","author":"Mertens","year":"2007","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"14157","DOI":"10.1073\/pnas.1107747108","article-title":"Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85alpha Src homology-2 domains","volume":"108","author":"Lee","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S713","DOI":"10.1093\/ecco-jcc\/jjz206","article-title":"Molecular structure and function of Janus kinases: implications for the development of inhibitors","volume":"14","author":"Garrido-Trigo","year":"2020","journal-title":"J Crohns Colitis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.cell.2020.04.052","article-title":"SnapShot: Jak-STAT Signaling II","volume":"181","author":"Villarino","year":"2020","journal-title":"Cell"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jaut.2017.06.006","article-title":"Small molecules to the rescue: inhibition of cytokine signaling in immune-mediated diseases","volume":"85","author":"Gadina","year":"2017","journal-title":"J Autoimmun"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/1947601910397187","article-title":"Jak\/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies","volume":"1","author":"Jatiani","year":"2010","journal-title":"Genes Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1073\/pnas.86.5.1603","article-title":"Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction","volume":"86","author":"Wilks","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0378-1119(02)00398-0","article-title":"Signaling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"6374","DOI":"10.1073\/pnas.91.14.6374","article-title":"Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes","volume":"91","author":"Kawamura","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"112201","DOI":"10.1016\/j.celrep.2023.112201","article-title":"Structural basis of Janus kinase trans-activation","volume":"42","author":"Caveney","year":"2023","journal-title":"Cell Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"115162","DOI":"10.1016\/j.bcp.2022.115162","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19","volume":"202","author":"Huang","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref19","first-page":"75","article-title":"Jakafi (Ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: first approval","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","article-title":"Upadacitinib: first approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J Med Chem"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/1744666X.2022.2038134","article-title":"Tofacitinib for the treatment of active ankylosing spondylitis in adults","volume":"18","author":"Mohanakrishnan","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/cts.13146","article-title":"Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - analyses of phase III clinical trials","volume":"15","author":"Muensterman","year":"2022","journal-title":"Clin Transl Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying Antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/1744666X.2022.2060822","article-title":"The suitability of treating atopic dermatitis with Janus kinase inhibitors","volume":"18","author":"Narla","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2147\/DDDT.S340459","article-title":"Evaluating Upadacitinib in the treatment of moderate-to-severe active ulcerative colitis: design, development, and potential position in therapy","volume":"16","author":"Napolitano","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40265-019-01131-y","article-title":"Peficitinib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.3390\/molecules25153321","article-title":"Inside perspective of the synthetic and computational toolbox of JAK inhibitors: recent updates","volume":"25","author":"Coricello","year":"2020","journal-title":"Molecules"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate","volume":"69","author":"Kivitz","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/13543784.2017.1372422","article-title":"Filgotinib for the treatment of rheumatoid arthritis","volume":"26","author":"Taylor","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/DDDT.S287218","article-title":"The effectiveness of Ruxolitinib for acute\/chronic graft-versus-host disease in children: a retrospective study","volume":"15","author":"Yang","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1001\/jama.2022.9846","article-title":"Baricitinib is first approved COVID-19 immunomodulatory treatment","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL(\u00ae)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales","year":"2014","journal-title":"J Vet Pharmacol Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40265-022-01718-y","article-title":"Pacritinib: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/10600280231153863","article-title":"Deucravacitinib: the first FDA-Approved Oral TYK2 inhibitor for moderate to severe plaque psoriasis","volume":"58","author":"Truong","year":"2024","journal-title":"Ann Pharmacother"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/13543784.2021.2012149","article-title":"Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata","volume":"30","author":"Eisman","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"820586","DOI":"10.3389\/fped.2022.820586","article-title":"The safety and efficacy of Tofacitinib in 24 cases of pediatric rheumatic diseases: single Centre experience","volume":"10","author":"Kostik","year":"2022","journal-title":"Front Pediatr"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_349615","article-title":"Management of myeloproliferative neoplasms in the molecular era: from research to practice","volume":"42","author":"Pettit","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2009.50","article-title":"CYT387, a selective JAK1\/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients","volume":"23","author":"Pardanani","year":"2009","journal-title":"Leukemia"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s40265-024-02089-2","article-title":"Golidocitinib: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jmb.2009.01.041","article-title":"Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains","volume":"387","author":"Williams","year":"2009","journal-title":"J Mol Biol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J Med Chem"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1021\/acs.jmedchem.0c01952","article-title":"Structural insights into JAK2 inhibition by ruxolitinib, fedratinib, and derivatives thereof","volume":"64","author":"Davis","year":"2021","journal-title":"J Med Chem"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1158\/2159-8290.CD-11-0324","article-title":"Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent","volume":"2","author":"Andraos","year":"2012","journal-title":"Cancer Discov"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.1021\/jm8010299","article-title":"Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states","volume":"51","author":"Kufareva","year":"2008","journal-title":"J Med Chem"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1075192","DOI":"10.3389\/fimmu.2022.1075192","article-title":"Molecular dissection of Janus kinases as drug targets for inflammatory diseases","volume":"13","author":"Kwon","year":"2022","journal-title":"Front Immunol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1128\/MCB.20.10.3387-3395.2000","article-title":"Regulation of the Jak2 tyrosine kinase by its pseudokinase domain","volume":"20","author":"Saharinen","year":"2000","journal-title":"Mol Cell Biol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-13-0279","article-title":"Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors","volume":"20","author":"Meyer","year":"2014","journal-title":"Clin Cancer Res"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/bph.13096","article-title":"Ten things you should know about protein kinases: IUPHAR review 14","volume":"172","author":"Fabbro","year":"2015","journal-title":"Br J Pharmacol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jmb.2010.05.020","article-title":"Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6","volume":"400","author":"Chrencik","year":"2010","journal-title":"J Mol Biol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1016\/j.bmc.2018.08.005","article-title":"Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor","volume":"26","author":"Hamaguchi","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.1021\/jm501262q","article-title":"Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634","volume":"57","author":"Menet","year":"2014","journal-title":"J Med Chem"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1021\/acsmedchemlett.7b00154","article-title":"JAK2 JH2 fluorescence polarization assay and crystal structures for complexes with three small molecules","volume":"8","author":"Newton","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","article-title":"A review of safety outcomes from clinical trials of Baricitinib in rheumatology, dermatology and COVID-19","volume":"39","author":"Bieber","year":"2022","journal-title":"Adv Ther"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/17512433.2019.1615443","article-title":"JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis","volume":"12","author":"Qiu","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31138\/mjr.281123.fof","article-title":"Focus on filgotinib in rheumatoid arthritis: a trial-based review","volume":"35","author":"Skouvaklidou","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jphs.2016.12.001","article-title":"A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model","volume":"133","author":"Ito","year":"2017","journal-title":"J Pharmacol Sci"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e2300591","DOI":"10.1002\/ardp.202300591","article-title":"Structure-guided design of potent JAK1-selective inhibitors based on 4-amino-7H-pyrrolo[2,3-d]pyrimidine with anti-inflammatory efficacy","volume":"357","author":"Zhang","year":"2024","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12967-023-04443-6","article-title":"Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation","volume":"21","author":"Wang","year":"2023","journal-title":"J Transl Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/nsmb859","article-title":"Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition","volume":"11","author":"Ohren","year":"2004","journal-title":"Nat Struct Mol Biol"},{"key":"ref69","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem Biol Drug Des"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"13286","DOI":"10.1021\/ja902010p","article-title":"Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors","volume":"131","author":"Simard","year":"2009","journal-title":"J Am Chem Soc"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"114760","DOI":"10.1016\/j.bcp.2021.114760","article-title":"Targeting the JAK-STAT pathway in autoimmune diseases and cancers: a focus on molecular mechanisms and therapeutic potential","volume":"193","author":"Tzeng","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.18553\/jmcp.2022.28.9.1046","article-title":"Characteristics of adverse event reporting of Xeljanz\/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration","volume":"28","author":"Qian","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"176","DOI":"10.31083\/j.fbl2808176","article-title":"Different biomarkers of response to treatment with selective Jak-1 inhibitors in rheumatoid arthritis","volume":"28","author":"Benucci","year":"2023","journal-title":"Front Biosci (Landmark Ed)"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"152740","DOI":"10.1016\/j.semarthrit.2025.152740","article-title":"Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges","volume":"73","author":"Avouac","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1387585","DOI":"10.3389\/fphar.2024.1387585","article-title":"Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials","volume":"15","author":"Cai","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1716179\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:10:03Z","timestamp":1769411403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1716179\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":77,"alternative-id":["10.3389\/fmed.2026.1716179"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1716179","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"article-number":"1716179"}}